Harrow, a company focused on eye health solutions, recently announced impressive first-quarter results for 2026, showcasing strong demand for its products despite a downturn in the overall dry eye market. VEVYE, one of their key offerings, achieved record prescription levels, with a 170% increase in new prescriptions from a national pharmacy benefit manager. This surge is expected to contribute to projected revenues exceeding $100 million for the year, even as the company navigates a temporary revenue adjustment due to new commercial coverage.

This growth is significant for people dealing with eye conditions like dry eye disease, as it indicates that effective treatments are becoming more accessible. With VEVYE surpassing its competitor XIIDRA in prescriptions, individuals seeking relief from dry eye symptoms may find more options available. Additionally, the increase in demand for other products like IHEEZO and TRIESENCE suggests that Harrow is successfully expanding its market share, which could lead to better treatment options for various eye conditions.

The findings are based on early-stage financial results from Harrow’s first quarter, reflecting a promising trajectory but still requiring cautious optimism. The company anticipates a revenue range of $71 million to $81 million for the second quarter and has reaffirmed its full-year revenue guidance between $350 million and $365 million. While these figures are encouraging, they are based on current market conditions and demand, which can fluctuate.

For those interested in eye health, staying informed about new treatments and their availability is essential. If you’re experiencing dry eye symptoms, consider discussing the latest options with your eye care provider, as advancements in the industry may lead to more effective solutions.

Source: globenewswire.com